The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.
The recognition of microRNAs with a Nobel Prize was a welcome surprise for some researchers. In 2006, the Nobel committee awarded the medicine or physiology prize to two researchers for their ...
The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.